Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells

SIMPLE SUMMARY: Venetoclax is an antagonist of the antiapoptotic protein Bcl-2, and is currently approved for treatment of chronic lymphocytic leukemia (CLL). Recently, clinical use has shown that patients develop resistance to venetoclax. Therefore, the demand for novel targets for treatment of CLL...

Descripción completa

Detalles Bibliográficos
Autores principales: Avsec, Damjan, Jakoš Djordjevič, Alma Tana, Kandušer, Maša, Podgornik, Helena, Škerget, Matevž, Mlinarič-Raščan, Irena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466897/
https://www.ncbi.nlm.nih.gov/pubmed/34572784
http://dx.doi.org/10.3390/cancers13184557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466897/
https://www.ncbi.nlm.nih.gov/pubmed/34572784
http://dx.doi.org/10.3390/cancers13184557

Ejemplares similares